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Abstract
Chlamydia trachomatis is the most common bacterial sexually-transmitted infection in the United
States. This disease disproportionately affects adolescent minority women, and untreated infection
can lead to lasting reproductive tract morbidity. Recommendations for primary prevention include
patient counseling to decrease risky behavior and increase barrier protection use; secondary
prevention recommendations include screening and treatment of affected individuals and their
sexual partners, barrier contraception use, as well as counseling to decrease behaviors that lead to
re-infection. Despite these strategies, both incidence and prevalence of Chlamydia have continued
to escalate in this population. Interventions to decrease chlamydial infection should encompass all
facets of primary and secondary prevention as well as address the fundamental barrier to
prevention – lack of perception of risk in this young age group.
THE BURDEN OF DISEASE
Approximately 19 million new sexually-transmitted infections (STIs) occur each year in the
United States; almost half are among young adults aged 15 to 24 years(1). The U.S.
prevalence of Chlamydia trachomatis is 4.2% in young adults with the greatest number of
cases (325,000) affecting women under 20 years of age (2). Given the treatable nature of the
disease and the potential for reproductive health consequences of untreated infection, the
Centers for Disease Control and Prevention (CDC), U.S. Preventive Services Task Force
(USPSTF), American Congress of Obstetricians and Gynecologists (ACOG), and American
Academy of Family Physicians (AAFP) recommend annual screening for all sexually active
women younger than 26 years (Table 1) (3). Thus far, recommendations alone have not
decreased the national burden of disease.
Ethnic minorities are disproportionately affected by chlamydial infection. African-
Americans represent approximately 12% of the U.S. population, but account for nearly half
of all infections. Hispanics comprise 15% of the U.S. population, but account for 19% of all
reported chlamydial cases (1). Directed efforts to decrease the disease burden in these
minority young women have not diminished this discrepancy.
Chlamydial infection rates increased from 87 to 370 cases per 100,000 persons between
1988 and 2007. Among women, the highest age-specific rates in 2007 were among those 15
to 19 years of age (3,000 cases per 100,000 females). Among sexually active youth aged 15
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to 29 years, the cost of STIs in the U.S. approximated $6.5 billion in 2000 (1). Chlamydial
infections alone contributed $250 million in direct expenses, including treatment of infection
and complications from undiagnosed and untreated infection. These estimates do not
account for indirect nonmedical costs such as productivity loss, pain, and suffering. Given
that many chlamydial infections are often unreported and the rate of STI acquisition in this
age group is escalating, this underestimates the true cost to the U.S. health system (1).
The most significant effects on disease burden will result from efforts directed towards those
most affected: urban minority female adolescents, aged 15–19 years. Successful prevention
efforts to decrease disease prevalence among this subpopulation have the potential to lower
national statistics. Both health care providers and young women may underestimate the
scope and impact of this infection. Modification of individual and group adolescent behavior
in conjunction with treatment of existing infection must occur if disease burden is to
decrease. This review will address primary and secondary prevention of chlamydial
infection as it pertains to this high-risk group, as well as innovative prevention strategies for
this young population.
PREVENTION STRATEGIES
Strategies aimed at reducing the disease burden among adolescents include both primary and
secondary prevention. Primary prevention efforts focus on decreasing disease acquisition
through counseling and education to reduce sexual risk behavior, and increase use of barrier
methods. In 1993, the CDC recommended that health care providers assess the risk of
reproductive-aged female patients and provide patient education on delaying age at first
intercourse, reducing the number of sexual partners, promoting use of condoms, choosing
low-risk sexual partners, and encouraging mutually monogamous relationships (4). In 2006,
the CDC outlined the use of open-ended questions when eliciting a sexual history and
encouraged interactive individually-tailored counseling (3).
Secondary prevention efforts are intended to detect and treat existing disease as well as
prevent re-infection. Efforts include counseling and barrier method use (to decrease re-
infection) as well as screening and treatment of infected individuals and their sexual
partners. In all 50 states and Washington D.C., minors aged 14 years and older may request
STI screening without parental consent. Consent laws for minors’ contraceptive services,
however, vary from state to state (www.guttmacher.org). Promotion of counseling to
decrease risk behavior, barrier method use, and screening for Chlamydia are almost
universally recommended by national agencies. However, their utility and potential for
decreasing disease burden are difficult to quantify.
PATIENT COUNSELING
Counseling of adolescents must occur in conjunction with screening tests, regardless of
results, and the promotion of barrier condom use. These counseling efforts must be directed
at obstacles that prevent teens from seeking screening and, more importantly, the multiple
risk factors for STI acquisition. Adolescents may be less forthcoming with their sexual
histories, and providers need to address sexual behavior with all young patients. The CDC
recommends straightforward and nonjudgmental questioning when eliciting a sexual history
and outlines a strategy for obtaining this history in the 2006 STD Treatment Guidelines (3).
Providers must understand the sexual behavior of young women, and address barriers such
as fear of social stigma, fear of abuse by a sexual partner, and the adolescent developmental
mindset of invulnerability.
Choice of sexual partner, cultural and ethnic differences, and fear of potential abuse may
decrease an adolescent’s likelihood of seeking screening and impair ability to negotiate
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condom use with sexual activity (5). Adolescent females with older male partners (compared
to similar-aged partners) less often report consistent condom use; these women may have the
highest risk of acquiring STIs (6–9). Among Latino adolescents, condom use is consistently
lower than in African-American or Caucasian teens (10–12). Adolescents are more likely to
use condoms with a partner they see as casual as compared to one they consider a long-term
partner (13–15).
Data from the National Longitudinal Study of Adolescent health found that only 14% of all
respondents and only 33% of those infected with an STI reported perceiving that they were
at risk for STIs at time of diagnosis (16). Decreasing sexual risk behavior is perhaps the
largest obstacle to overcome. To reduce prevalence of Chlamydia trachomatis and other
STIs in this population, efforts must be directed toward this fundamental barrier – an
adolescent’s lack of perception for disease risk (17). Intervention programs designed to
alter an individual’s sexual risk perception are often founded on adolescent developmental
theory and confront the mindset of invulnerability (18).
The NIH Consensus Development Statement (1997) supports the need to develop effective
behavioral interventions for this population, with particular attention to language and
cultural barriers (19, 20). One successful intervention program, “Sister to Sister”, included
an individual session between the client and nurse facilitator, showed brief videos, included
condom-use demonstration, and used role-play to support behavioral change. The
intervention was successful among African-Americans in decreasing sexual risk behaviors
during the study period, including greater reported condom use 12 months later, and
decreased acquisition of STIs (21, 22). Counseling, both individually tailored and designed
for use in a busy clinical setting, are key areas for future investigation.
BARRIER METHODS
Consistent and correct use of male condoms is routinely recommended for preventing STI
transmission (1). Latex condoms are effective mechanical barriers, virtually impermeable to
sexually-transmitted pathogens (23, 24). When used by couples discordant for disease,
condoms substantially decrease the transmission of Chlamydia trachomatis (25).
Although recognized as an effective prevention method, condom use remains inconsistent
among adolescents and young adults. One study of African-American teens aged 14 to 18
years treated those diagnosed with Chlamydia trachomatis, Neisseria gonorrhoeae, or
trichomoniasis then retested them 6 months later if coitus was reported. In this sample of
380, 18% of those who reported consistent condom use with intercourse had at least one STI
compared to 30% of those reporting inconsistent or no condom use (26). In contrast, two
other prospective observational studies, one specific to adolescents and the other among an
urban STI clinic population, did not find significantly different STI incidences between
those who did and did not report consistent condom use (27, 28).
Surveys of patient behavior may be affected by social desirability bias - the tendency to
report behavior that is viewed positively by others. Participants may over-report condom use
or fail to report breakage, underestimating STI exposure (25, 29). Unknown partner
infection status (and thus unknown exposure status) is difficult to quantitatively measure.
Surrogate markers of exposure typically used – reported exposure, perceived high-risk
partner, multiple partners, for example – may be invalid estimates of true exposure (30).
Limited information exists on the effectiveness of the female condom for STI prevention. A
systematic review of the female condom reports that while acceptability in vulnerable
populations has been demonstrated, use of the female condom may be lessened by increased
cost and decreased availability as compared to the male condom (31). The female condom
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has been shown to decrease the reported number of unprotected sex acts, but information on
slippage and breakage is lacking. To date, randomized trials of STI prevention with use of
the female condom have failed to demonstrate consistent benefit. The female condom is still
recommended, however, as a method to decrease STI transmission and to prevent unplanned
pregnancy as it augments a woman’s choices for contraception and safe sexual practices
(31).
SCREENING
Screening can be performed during routine physical exam visits, emergency room
encounters, contraceptive counseling appointments, and primary care evaluations. The
impetus for frequent screening in adolescents is derived from the high burden of disease and
high re-infection rate among young females.
Screening rates for Chlamydia trachomatis among young women in the U.S. remain low
despite recommendations by the CDC and USPSTF. In 2007, a review of nationwide
insurance claims revealed that the annual screening rate was 42% for young females (32).
Screening rates were lowest in the Southern United States (37%) and highest in the
Northeast (46%). The true rate may be even lower than reported, as those without health
insurance may be even less likely to access care (i.e., minority young women).
Provider adherence to Chlamydia trachomatis screening guidelines for adolescent and young
adult women is inadequate. A review of the National Ambulatory Medical Care Survey in
2005 revealed that obstetricians-gynecologists did not perform screening at 69% of visits
where pelvic exams were performed and 71% of visits with Papanicolaou smears for women
aged 15 to 25 yr. (33). Primary care physicians did not perform urine screening tests at 99%
of visits when urinalyses (for reasons other than Chlamydia trachomatis screening) were
performed (33).
A 2009 systematic review specific to chlamydial and gonorrheal re-infection among
adolescent women reported a median re-infection rate of almost 14%. Re-infection peaked at
13 months after initial diagnosis, and a consistent trend of higher re-infection rates was
noted among younger ages (34). These findings suggest that young women diagnosed with
chlamydial infection should be retested 3–6 months after initial infection and treatment (34).
The CDC encourages re-screening 3–6 months after diagnosis and treatment – the impetus
for re-screening is the high incidence of re-infection (35, 36). The USPSTF makes no
recommendation as to early re-screening for those who test positive (37).
A recent analysis suggests frequent rescreening is cost effective (38). This analysis projected
that annual screening prevents 864 cases of chronic pelvic pain, 967 cases of tubal
infertility, and 435 cases of ectopic pregnancy per 100,000 women versus no annual testing.
Rescreening 3–6 months after treatment of documented infection prevents an additional 64
cases of chronic pelvic pain, 72 cases of tubal infertility, and 32 cases of ectopic pregnancy
per 100,000 women. Annual screening with rescreening for those diagnosed with
Chlamydia trachomatis within 3–6 months proved the most cost-effective strategy (38).
Potential harms of screening include the risk of false-positive testing and stigma of
diagnosis. While the risk for false-positive testing is low, given the high disease prevalence
in this high-risk population, a false-positive screen could result in inappropriate antibiotic
therapy. Endocervical culture and urine nucleic acid amplification tests are both highly
specific, 98% and 95%, respectively; culture is slightly less sensitive than urine testing.
Antibiotic therapy with single-dose azithromycin, 1 gm P.O., is well-tolerated in those
without allergic sensitivity and is nearly 100% effective (39). Potential psychological harms,
such as stigma associated with diagnosis and potential repercussions in a sexual relationship,
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are difficult to quantify and likely under-reported. Overall, the benefits of screening appear
to outweigh the potential harms, but screening remains only one part of the solution to a
growing epidemic of STI infection among adolescents and young adults.
OPPORTUNITIES TO IMPROVE
Increasing the annual screening rate in this population to 50% - up from the current 42% -
may decrease the missed diagnoses from 2543 to 2100 with a subsequent reduction in
sequelae (32). While only a rough estimate, meeting current screening recommendations has
important public health implications. Missing from these estimates, however, is the impact
of individual behavior – from both providers and this high-risk population.
Pairing screening with Papanicolaou smears is a promising method for improving
Chlamydia trachomatis surveillance
A retrospective cohort from a large group health plan showed rates of Chlamydia screening
increased if providers performed testing during speculum examinations for Papanicolaou
smears (40). The greatest rate of increase was in women aged 20 – 26 (24% increase), with a
more modest increase in women aged 15 – 19 years (10% increase) (40). These findings
underscore that increasing screening rates is feasible when paired with cervical cancer
screening and a need for improvement persists in screening rates in young adolescents.
Pairing urine Chlamydia trachomatis screening with urine pregnancy tests for adolescents
is a largely untapped opportunity
Risk factors for unplanned pregnancy mirror those of chlamydial infection, but few studies
have evaluated frequency of STI screening at time of pregnancy testing. One recent study
evaluated 1465 participants and found that 12% were diagnosed with Chlamydia trachomatis
at the time of urine pregnancy testing, regardless of pregnancy diagnosis (41). In addition,
those diagnosed with chlamydial infection were younger and of African-American ethnicity.
Urine screening is simple and non-invasive as a urine sample is already collected for
pregnancy testing.
Urine testing, rather than endocervical testing, may increase the acceptability of screening.
A prospective cohort of adolescents in an urban emergency department indicated that
urinary screening was acceptable to the majority of adolescents irrespective of the reason for
emergency care. Of 1231 adolescents aged 14 to 20 years who were approached upon
admission to the emergency department, 71% consented to undergo urine screening (42).
Other opportunities, such as emergency room or provider visits for unrelated complaints,
may increase screening in this population. Additional information, such as cost-effectiveness
projections, is likely necessary before widespread implementation can be promoted.
While none of these studies was a randomized masked clinical trial, which is the gold
standard study design, each offers compelling evidence to increase screening in ways that
are easily adaptable to busy clinical settings. A summary of the evidence can be found in
Table 2.
THE FUTURE
The USPSTF recognizes the lack of research regarding the negative outcomes of screening –
the stigma of diagnosis and the impact of false-positive results. Consistent evidence for
screening and treatment of adolescent males is lacking. As young women most frequently
contract Chlamydia trachomatis through heterosexual behavior, primary prevention through
disease identification in male partners is a potential area for improvement (15). To date,
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widespread screening and treatment of adolescent males is not supported by cogent research
(3).
Analysis of the evidence for screening, condom use, and counseling illustrates some of the
uncertainties underlying both primary and secondary prevention. Strategies should be aimed
at increasing adherence to national recommendations by providers and patients, as neither
appears to fully appreciate the repercussions of untreated disease. Implementation of
primary prevention strategies through behavioral change in partner selection, delaying first
intercourse, and consistent condom use has proven difficult. Secondary prevention
strategies, including screening and behavioral counseling at the time of clinical evaluation
for both gynecologic and unrelated complaints, are also largely untapped opportunities.
Developmentally appropriate interventions to improve an adolescent’s perception of sexual
risk, coupled with improving adherence to recommendations, may be keys to decreasing
disease burden in this young, underserved, minority population.
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Table 1
Guidelines for Chlamydia Screening
Organization Year Recommendations for Screening Interval
USPSTF* (AAFP)+ 2007 • all sexually active women aged 24 and younger
• all older women at increased risk
• pregnant women at first prenatal visit if 24 and younger or at







2006 • all sexually active women aged 25 and younger
• all older women at increased risk
Annual; retest all patients
with new infection at 3–
12 months after treatment
ACOG⇞ (Cites USPSTF
2001, CDC 2006)
2006 • all sexually active women aged 25 and younger
• all older women at increased risk
Annual
*
Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007;147(2):128–34.
+
Meyers D, Wolff T, et al. USPSTF recommendations for STI screening. Am Fam Physician 2008;77(6):819–24.
⤒
Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006 Aug 4;55(RR-11):1–94.
⇞
ACOG Committee Opinion No. 357: Primary and preventive care: periodic assessments. Obstet Gynecol 2006; 108(6):1615–22.
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